Proteins involved in the Rho-signaling cascade are significantly elevated in a variety of cancers [39-43], and pharmacological inhibition of ROCK activity shows preclinical efficacy in the treatment of in vivo malignancies including prostate, breast, glioma, melanoma, and human papillomavirus infected tumors [25, 44-47]. Here, RHO is linked to central nervous system cancer.